Randomized phase III trial of Herceptin™ followed by Taxol plus Herceptin™ versus the combination of Herceptin™ and Taxol as palliative chemotherapy in patients with HER2-overexpressing advanced breast cancer
Nov 1, 1999
To compare efficacy, toxicity and quality of life of the sequential administration of Her alone followed, at PD, by the combination with weekly Tax (Arm A) vs. the upfront combination of both drugs (Arm B) in patients with ABC.
Clinical Studies -
Nov 1, 1999 - Nov 1, 2015
Automatically Closed
Project leader: Ruhstaller Thomas
Members: Baumann Michael
more
